SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is a major talking point following news of Amazon Pharmacy offering Novo Nordisk's oral GLP-1 weight-loss pill, intensifying competitive concerns for HIMS which does not offer the product. This development, alongside a recent analyst downgrade, is fueling a deeply divided community, with many anticipating further declines while bullish investors view the significant pullback as an overblown reaction and a strategic long-term buying opportunity in the evolving telehealth market.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is actively trending following positive regulatory feedback that significantly de-risks its lead drug, sonelokimab, by allowing a Biologics License Application filing without additional trials. This pivotal development, coupled with recent analyst upgrades and upcoming investor events, has fueled extensive community speculation about a potential strategic acquisition, with many anticipating substantial upside from the biotech's de-risked asset.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending amidst extreme price plunges, largely driven by persistently warm winter forecasts and ample natural gas supplies. The community is expressing widespread despair over significant losses, with many desperately hoping for an "arctic blast" or "polar vortex" to reverse the devastating trend for this highly volatile, leveraged ETF, while others question its long-term viability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with heightened anticipation for its J.P. Morgan Healthcare Conference presentation, where updates on Briumvi's robust market adoption and 2026 guidance are highly awaited. Community sentiment is also notably buoyed by recent competitor setbacks that underscore Briumvi's strong profile, leading to active discussions around potential strategic acquisitions and the influence of short positions.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings (VWAV) is generating significant buzz following a series of strategic developments in its AI, defense, and drone technology sectors, including recent patent grants and acquisitions. The community is highly bullish, anticipating a major "parabolic" move or short squeeze driven by the stock's extremely low float and high institutional ownership, with many drawing comparisons to past high-growth stocks. Investors are also noting its "Strong Buy" rating from Nasdaq Dorsey Wright and successful pilot programs, signaling strong potential for commercialization and growth.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as the market closely watches unfolding developments in Venezuela, with the US administration signaling that American oil companies could be heavily involved in revitalizing the nation's vast oil reserves. This potential for asset recovery and new investment is fueling bullish sentiment and discussions of significant upside. However, community conversations also highlight widespread concerns regarding market oversupply, political complexities, and the long-term feasibility of such ventures.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited is trending due to recent news of a private placement and a significant acquisition, alongside the expiration of its IPO lock-up period. This low-float Hong Kong stock has ignited a fierce debate within the community, with many anticipating a short squeeze reminiscent of other volatile "China plays," while others warn of a rapid pump-and-dump scenario.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is generating significant buzz due to a special cash dividend, the strategic involvement of investor David Lazar, and high short interest fueling short squeeze speculation. The community is sharply divided, with many anticipating substantial upside while others warn of a pump-and-dump. Conversation is also driven by recent filings hinting at a strategic pivot towards blockchain or financial infrastructure, comparing NBY to other low-float, high-volatility plays.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is actively trending as the community eagerly awaits news on its BLA resubmission for deramiocel, following strong HOPE-3 trial data for Duchenne muscular dystrophy. While many express confidence in an eventual FDA approval and significant upside potential, others voice concerns regarding perceived delays in the filing and potential regulatory hurdles. This ongoing dialogue reflects broader sentiment in the biotech sector where rare disease treatments are under scrutiny, balancing promising clinical results with regulatory timelines and market dynamics.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid intense community debate surrounding an ICE agent's fatal shooting in Minneapolis, with newly analyzed footage fueling polarizing arguments about justified force versus alleged government overreach. This contentious environment is further amplified by ongoing discussions about the release of "Epstein files" and President Trump's recent engagement with oil executives regarding Venezuela's energy sector. The stock remains highly sensitive to these significant political and social controversies, influencing investor sentiment and trading conversations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Options Traders Betting on a Big Move in Delcath Systems Stock?

Investors need to pay close attention to DCTH stock based on the movements in the options market lately. 

Simplify Asset Management Inc. Increases Stock Position in Delcath Systems, Inc. $DCTH

Simplify Asset Management Inc. increased its holdings in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 144.9% during the third quarter, according to its most recent filing with the Securities...

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Analysts

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat reports. One investment...

Vivo Capital LLC Decreases Stake in Delcath Systems, Inc. $DCTH

Vivo Capital LLC cut its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 24.1% during the second quarter, according to the company in its most recent filing with the...

Delcath Systems, Inc. $DCTH Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC boosted its holdings in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 128.1% during the second quarter, according to its most recent Form 13F filing with the SEC...

Do Options Traders Know Something About Delcath Systems Stock We Don't?

Investors need to pay close attention to Delcath Systems stock based on the movements in the options market lately.

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat.com...

Delcath Systems (NASDAQ:DCTH) Board Authorizes Stock Repurchase Plan

Delcath Systems (NASDAQ:DCTH - Get Free Report) announced that its Board of Directors has approved a share repurchase program on Thursday, November 20th, RTT News reports. The company plans to...

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Delcath Systems, Inc. (Nasdaq: DCTH), (Delcath) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors...

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Delcath Systems, Inc. (Nasdaq: DCTH), (Delcath or the Company) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$10.34
Prev Close	$10.21
Open	$10.31
Dividend Yield	0.00%
50-Day Moving Average	$9.58
Beta	1.08
Avg. Volume	496,819.64
PE Ratio	1,187.21

52-Week High	$18.23
52-Week Low	$8.12
Market Capitalization	$360.55M
EPS (Annual)	-$0.9254
Price to Book	3.14
Revenue Per Employee	$387,552.08
Enterprise Value/EBITDA	N/A

DCTH
Delcath Systems Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DCTH News

DCTHDelcath Systems Inc